Comment from Daiichi Sankyo

Summary: Daiichi Sankyo, a global pharmaceutical company, submitted comments providing specific technical feedback and requests for clarification on the draft guidance for master protocols. They advocate for more detailed guidance on oncology trials, randomization practicalities, and the inclusion of combination regimens.